GO:0019882 antigen processing and presentation guide

Antigen processing and presentation (GO:0019882) is the biological process in which an antigen-presenting cell expresses antigen, either peptide or lipid, on its cell surface in association with an MHC protein complex. This process is the molecular bridge between innate sensing of pathogens or tumors and adaptive T-cell immunity, and it determines whether the immune system mounts an effective response or tolerates a given antigen. Because the repertoire of peptides displayed on MHC molecules, often called the immunopeptidome, reflects the intracellular and extracellular environment of a cell, antigen processing and presentation is a central node in infection, autoimmunity, transplantation, and cancer immunology. Mechanistically, antigen processing and presentation is divided into the MHC class I pathway, which samples cytosolic and nuclear proteins for CD8+ T cells, and the MHC class II pathway, which samples endosomal and lysosomal proteins for CD4+ T cells. Specialized antigen-presenting cells, including dendritic cells, macrophages, and B cells, can also cross-present exogenous antigens on MHC class I, a process essential for immunity to tumors and many viruses. The pathway is highly regulated at the level of antigen degradation, peptide transport, MHC loading, and surface trafficking, and its dysregulation is a hallmark of immune evasion in cancer and chronic infection. For researchers, GO:0019882 provides a structured framework to study how genetic perturbations alter immune recognition. Knockout of transporters associated with antigen processing (TAP), proteasome subunits, or MHC genes collapses specific presentation routes, while point mutations in MHC-binding pockets or catalytic residues of processing enzymes can separate peptide generation from peptide loading. Understanding these steps at molecular resolution is prerequisite to designing neoantigen vaccines, T-cell engagers, and checkpoint therapies, and it explains why antigen presentation defects predict resistance to immunotherapy.

In plain terms, antigen processing and presentation is the cellular process in which an antigen-presenting cell expresses antigen, either peptide or lipid, on its cell surface in association with an MHC protein complex. The term encompasses the proteolytic and chaperone-assisted steps that generate antigenic fragments, their transport to the appropriate MHC-loading compartment, and the surface display of the resulting peptide-MHC or lipid-MHC complex for recognition by T cells or other immune receptors.

Antigen processing and presentation is important because it determines which antigens the immune system can see and respond to, thereby controlling host defense, tumor surveillance, autoimmunity, and vaccine efficacy. Every T-cell-based therapy, from checkpoint blockade to neoantigen vaccines, depends on the fidelity of this pathway, and its perturbation is a common mechanism of immune escape in cancer and chronic viral infection.

The following genes and proteins are core components of antigen processing and presentation and are frequently studied in immunology and immuno-oncology research.

Antigen processing and presentation is regulated at multiple levels. Transcription of MHC class I genes is controlled by the NLRC5 transactivator, while MHC class II genes are controlled by CIITA, which integrates interferon-gamma and other inflammatory signals. Interferons also induce immunoproteasome subunits and TAP, enhancing peptide supply for class I loading. Post-translationally, the stability and trafficking of peptide-MHC complexes are regulated by ubiquitination, endosomal recycling, and chaperone availability, and HLA-DM and HLA-DO tune the class II peptide repertoire. In tumors, epigenetic silencing, mutations in B2M or TAP, and altered interferon signaling reduce antigen presentation and drive immune evasion.

Tumors frequently evade immune destruction by disrupting antigen processing and presentation. Loss-of-function mutations in B2M, TAP1, TAP2, or HLA class I genes abolish surface peptide-MHC class I complexes and prevent CD8+ T-cell recognition, and such defects are associated with primary and acquired resistance to checkpoint blockade. Downregulation of MHC class II and impaired cross-presentation also limit CD4+ T-cell help and dendritic-cell priming of antitumor responses. Conversely, tumors with intact antigen presentation and high neoantigen load are more likely to respond to immunotherapy, making this pathway a predictive biomarker and a therapeutic target.

HIV and other chronic viruses manipulate antigen processing and presentation to avoid cytotoxic T-lymphocyte clearance. HIV Nef downregulates surface MHC class I and interferes with antigen processing, while viral variation in epitopes alters peptide loading and T-cell receptor recognition. These mechanisms contribute to viral persistence and to the difficulty of designing T-cell-based vaccines, and they motivate research into how antigen processing genes shape antiviral immunity.

Aberrant antigen processing and presentation can break self-tolerance and drive autoimmunity, as seen with ERAP1 and HLA risk alleles in spondyloarthritis and other disorders, where altered peptide trimming changes the self-peptide repertoire. In the opposite direction, inherited defects in TAP, immunoproteasome subunits, or MHC expression cause immunodeficiency with impaired CD8+ T-cell responses, highlighting the non-redundant roles of these components in human immunity.

Recognition of allogeneic MHC-peptide complexes by recipient T cells is the central event in transplant rejection, and the density and composition of donor peptide-MHC complexes influence rejection kinetics. Understanding antigen processing in donor and recipient cells informs matching strategies and immunosuppressive regimens, and it is a rationale for engineering hypoimmunogenic cells for regenerative medicine.

Immunopeptidomics uses immunoaffinity purification of MHC molecules followed by liquid chromatography-tandem mass spectrometry to identify the peptides displayed on the cell surface. This method directly reads out the immunopeptidome and can quantify how knockout or point mutation of antigen processing genes changes peptide repertoire, length distribution, and binding motifs.

Flow cytometry with antibodies against HLA class I, HLA-DR, or CD1d measures surface antigen presentation at single-cell resolution and is widely used to validate CRISPR perturbations. It can be combined with intracellular staining for TAP, calnexin, or cathepsins to assess processing compartments.

Functional readouts such as T-cell receptor reporter assays, interferon-gamma ELISpot, and cytotoxicity assays measure whether altered antigen presentation translates into changed T-cell recognition. These assays are essential to link molecular changes to immunological outcomes and are commonly paired with CRISPR-edited antigen-presenting cells.

Confocal and super-resolution microscopy with tagged MHC molecules, CD74, or LAMP1 visualizes the trafficking of peptide-MHC complexes through the endoplasmic reticulum, Golgi, and endolysosomal system. Live-cell imaging of tagged knock-in lines provides dynamic information about loading and surface delivery.

Researchers studying antigen processing and presentation-related genes often need to determine whether a candidate gene is causally involved in peptide generation, MHC loading, or surface display, and whether a specific variant alters immune recognition. EDITGENE provides publication-grade CRISPR cell models and screening services to answer these questions with rigor and reproducibility.

Antigen processing and presentation (GO:0019882) is the central biological process that converts intracellular and extracellular antigens into peptide or lipid complexes displayed on MHC molecules for immune recognition. Its molecular dissection has revealed distinct class I, class II, cross-presentation, and lipid presentation routes, each with dedicated genes and regulatory layers. Because tumors, viruses, and autoimmune conditions exploit or depend on this pathway, it is a high-value target for mechanistic research and therapeutic intervention. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with immunopeptidomics and functional T-cell assays, provide the tools needed to define causality within this pathway. EDITGENE supports these efforts with validated cell models, library screening, and bioinformatics tailored to antigen processing and presentation research.